Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-Current Debt
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CureVac N.V (CVAC) Asset Writedowns and Impairment: 2021-2024

Historic Asset Writedowns and Impairment for CureVac N.V (CVAC) over the last 2 years, with Dec 2024 value amounting to -$4.9 million.

  • CureVac N.V's Asset Writedowns and Impairment rose 12.13% to -$4.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.2 million, marking a year-over-year increase of 199.06%. This contributed to the annual value of $37.7 million for FY2024, which is 1321.62% up from last year.
  • Per CureVac N.V's latest filing, its Asset Writedowns and Impairment stood at -$4.9 million for Q4 2024, which was down 127.54% from $17.8 million recorded in Q3 2024.
  • In the past 5 years, CureVac N.V's Asset Writedowns and Impairment ranged from a high of $17.9 billion in Q1 2022 and a low of -$44.8 billion during Q4 2021.
  • In the last 3 years, CureVac N.V's Asset Writedowns and Impairment had a median value of $1.2 million in 2023 and averaged $90.5 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 99.99% in 2023, then soared by 2,008.57% in 2024.
  • Quarterly analysis of 4 years shows CureVac N.V's Asset Writedowns and Impairment stood at -$44.8 billion in 2021, then spiked by 99.92% to -$35.4 million in 2022, then soared by 84.23% to -$5.6 million in 2023, then rose by 12.13% to -$4.9 million in 2024.
  • Its Asset Writedowns and Impairment was -$4.9 million in Q4 2024, compared to $17.8 million in Q3 2024 and -$5.6 million in Q4 2023.